AlphaYou
Overview
Smart money at a glance
Filings to Oct 5, 2026Net selling: insiders sold $1.3M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$1.3M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 1 added, 0 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- 10+ awardsAwards on record
Market overview
Fundamentals Oct 5- Open
- $44.94
- 52-wk high
- $60.91
- High
- $46.09
- 52-wk low
- $29.45
- Low
- $44.41
- Prev close
- $44.19
- Mkt cap
- $3.68B
- P/E
- 32.7x
- Volume
- 1.04M
- Fwd P/E
- 23.6x
- Beta
- 1.93
- P/S
- 6.5x
- P/B
- 2.5x
- Profit margin
- +20.4%
- Op margin
- +15.3%
- ROE
- +8.8%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about VCYT filings
Are insiders buying or selling Veracyte Inc (VCYT) stock?
Net selling: insiders sold $1.3M and bought $0 of VCYT stock on the open market in the 90 days to Oct 5, 2026, according to SEC Form 4 filings. $1.3M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Febbo, Phillip G. (Chief Scientific & Med Officer), who sold $564K. The latest filing was on Sep 22, 2026.
Which members of Congress have traded VCYT recently?
None. No member of Congress disclosed a VCYT trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this VCYT smart-money data?
This summary uses filings available on Oct 5, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (1)
- P7
Point72
$27.7M
added
What insiders are doing
How top traders are positioned
No tracked top-trader positions in VCYT right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 25.1% above what analysts expected.
Last report
Jul 30, 2026
Period ending
Jun 30, 2026
Adjusted EPS
$0.43 expected
Revenue
No reported revenue on record
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 30, 2026 | $0.54 / $0.43Yahoo Finance | +25.05% beat | Unavailable | Unavailable |
| Mar 31, 2026 | May 5, 2026 | $0.52 / $0.33Yahoo Finance | +56.02% beat | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 25, 2026 | $0.53 / $0.41Yahoo Finance | +29.79% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 4, 2025 | $0.51 / $0.32Yahoo Finance | +59.52% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 6, 2025 | $0.44 / $0.30Alpha Vantage | +46.67% beat | Unavailable | Unavailable |
| Mar 31, 2025 | May 7, 2025 | $0.31 / $0.20Alpha Vantage | +55.00% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 24, 2025 | $0.36 / $0.26Alpha Vantage | +40.02% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 6, 2024 | $0.33 / $0.17Alpha Vantage | +94.12% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Reports Nov 3, 2026, in 29 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $131.9M | $140.6M | $139.1M | $150.3M |
| Cost of what it sold | $40.6M | $36.0M | $38.5M | $41.8M |
| Gross profit | $91.3M | $104.7M | $100.6M | $108.6M |
| What it spent | ||||
| Research and development | $16.0M | $20.8M | $27.1M | $29.4M |
| Sales and admin | $43.2M | $1.4M | $23.7M | $27.4M |
| Other operating costs | $9.1M | $56.5M | $26.0M | $28.7M |
| Total operating expenses | $68.3M | $78.7M | $76.7M | $85.6M |
| What was left | ||||
| Operating profit | $22.9M | $25.9M | $23.8M | $23.0M |
| Interest on debt | $0 | $0 | $0 | $0 |
| Profit before tax | $18.9M | $40.6M | $30.0M | $19.4M |
| Tax | -$248.0K | -$515.0K | $1.3M | -$6.0M |
| Net profit | $19.1M | $41.1M | $28.7M | $25.5M |
| EBITDA | $24.2M | $45.9M | $35.4M | $24.3M |
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage leans bullish
Preferred dividends of Veracyte, Inc. – HAN:12V
NeutralSep 30Veracyte’s Decipher test shows predictive value in prostate cancer
BullishSep 29For 44% with low scores, added hormone therapy showed no statistically significant benefit against 10-year cancer spread.
BullishSep 29Eight studies will examine who with prostate cancer may benefit from more treatment
Leans bullishSep 26Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
BullishSep 25Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today
BullishSep 25Form 144 VERACYTE For: 25 September By Investing.com
NeutralSep 25A Veracyte (VCYT) director plans a $352,500 share sale after selling 5,000 shares.
Leans bearishSep 25
Macro
10 macro signals shaping VCYT right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results